When the Body Knows Something Is Wrong
Tens of thousands of women have reported the same experience: implants placed, followed months or years later by fatigue that doesn't resolve, cognitive changes, joint pain, hair loss, rashes, depression, and a growing list of symptoms that physicians — running standard labs, finding nothing obviously wrong — attribute to stress, anxiety, or the inevitable aging process. Meanwhile, the implants remain in place, and the symptoms continue.
Breast Implant Illness (BII) is the name given to this constellation of systemic symptoms believed to be caused or contributed to by breast implants. For years, it existed outside official medicine — documented in patient forums, reported to the FDA in thousands of Medical Device Reports, and dismissed in clinical settings. In August 2019, the FDA formally acknowledged BII in its communications to manufacturers and the public, requiring it to be listed on device labeling (FDA Safety Communication, August 2019). That acknowledgment arrived after decades of women being told their symptoms were psychological.
This page does not argue that every case of fatigue in a woman with implants is caused by the implants. It argues that the relationship between breast implants and systemic symptoms deserves serious clinical attention — the kind of attention that was structurally unavailable as long as BII was denied to exist at all.
What the FDA Acknowledged — and When
In October 2021, the FDA issued its most comprehensive action on breast implants to date, requiring manufacturers to add a boxed warning — the most serious warning the FDA places on medical devices — to breast implant labeling. The required language includes acknowledgment of:
- • Breast Implant Illness (BII) — a variety of systemic symptoms that may include fatigue, cognitive dysfunction, muscle and joint pain, rash, and depression
- • Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) — a type of non-Hodgkin lymphoma associated with breast implants (particularly textured surface implants)
- • Breast Implant-Associated Squamous Cell Carcinoma (BIA-SCC) — a rare cancer also identified in association with implants
- • A checklist requirement: patients must sign an informed consent checklist confirming they received and reviewed specific safety information
The boxed warning and patient decision checklist represent a formal medical acknowledgment that the informed consent historically provided for breast implant surgery was insufficient. Women were not being told what the FDA now requires them to be told. For women who had implants placed before 2021 — which is the majority of women with implants — that information was never provided.
What Dow Corning Knew — and When
The FDA's 2021 boxed warning is framed as new information. It is not. The core safety concerns — silicone migration to lymph nodes, immune system reactivity, long-term biological effects of silicone in tissue — were documented inside Dow Corning's own research files decades before the FDA acted. The question of why women were never told has a documented answer: the manufacturer knew, and did not disclose it.
Dow Corning Corporation — a joint venture between Dow Chemical and Corning Incorporated — began manufacturing silicone gel breast implants in 1962. They became the dominant supplier in the market and the company most central to the subsequent legal and scientific controversy. Internal Dow Corning documents obtained through litigation in the 1990s showed that company scientists had conducted animal studies and internal safety evaluations that raised concerns about silicone behavior in the body. Those documents showed silicone migration to regional lymph nodes in animal models. They showed internal discussion of biocompatibility questions. They showed awareness of the immune system's response to silicone particles in tissue. None of this was disclosed to the FDA, to surgeons, or to patients.
In 1992, FDA Commissioner David Kessler called for a voluntary moratorium on silicone gel implants — citing not evidence of proven harm but inadequate safety data. The FDA's position was that Dow Corning and other manufacturers had never adequately demonstrated that silicone gel implants were safe. The implants had been on the market for thirty years. No long-term safety studies had been required because the FDA had not regulated medical devices with the same rigor as drugs until the Medical Device Amendments Act of 1976 — by which time silicone implants had already been in widespread use for over a decade, and were effectively grandfathered.
Litigation followed. In 1994, a global settlement was reached in the breast implant mass tort — Multi-District Litigation 926 — involving Dow Corning, Bristol-Myers Squibb, Baxter International, 3M, and other manufacturers. The settlement totaled approximately $3.7 billion, structured to compensate women with documented implant-related injuries. It was one of the largest mass tort settlements in US history to that point. Dow Corning's share of the liability proved unmanageable. In May 1995, Dow Corning filed for Chapter 11 bankruptcy — driven primarily by breast implant litigation. The company did not emerge from bankruptcy until 2004, after nearly a decade of reorganization around that liability.
The internal documents uncovered through discovery — and subsequently reported in court proceedings and investigative journalism — established a pattern: a manufacturer aware of biological concerns, conducting internal studies that surfaced those concerns, and continuing to market the product and assure regulators of its safety without disclosing what the internal research showed. The pattern is not unique to Dow Corning. It is the same pattern documented in tobacco litigation, opioid litigation, and pharmaceutical mass tort cases. What makes the breast implant case notable is how clearly it connects to the present: the silicone migration to lymph nodes that Dow Corning's own animal research documented in the 1970s is the same migration now confirmed in explanted tissue and lymph node biopsy studies.
Women who had implants placed between 1962 and 1992 — and many placed after — were never told that the manufacturer had conducted internal studies raising migration and immune concerns, that the FDA had never formally reviewed long-term safety data before market entry, or that the device they received was never required to pass the same safety demonstration standard as a pharmaceutical drug. They consented to what they were told. They were not told what the company knew.
Current Implants: They Still Use Them — With New Chemistry
The FDA moratorium on silicone gel implants lasted fourteen years: 1992 to 2006. In 2006, the FDA re-approved silicone gel implants — Mentor and Allergan (then Inamed) — under conditions that required manufacturers to run long-term post-market safety studies. Those studies were required to follow women for ten years. In the years since, the FDA has repeatedly noted that manufacturers did not fully comply with those study commitments. The safety data that was supposed to arrive after the re-approval never came in complete form.
Today, three types of breast implants are in common use. Saline implants — filled with sterile saline, silicone shell — never left the market. Silicone gel implants returned after 2006. "Gummy bear" or cohesive gel implants — a newer generation of form-stable silicone — became widely available around 2012. All three types use silicone elastomer as the outer shell. None of them are chemically inert.
PFAS in Breast Implants
PFAS — per- and polyfluoroalkyl substances, the class of compounds known as "forever chemicals" — have been documented in association with breast implants. PFAS are used in industrial silicone manufacturing as processing aids and mold-release agents during the curing of silicone elastomer. The question is whether residual PFAS from the manufacturing process persists in the finished implant shell and whether it transfers to surrounding tissue.
A 2021 analysis by the Green Science Policy Institute reviewed PFAS in medical devices and found that fluoropolymer coatings — a category of PFAS — are present in a range of implantable medical devices. The FDA does not currently require manufacturers to test for or disclose PFAS content in implants. Women who received implants before 2020 were definitively not told about PFAS. Women receiving implants today are rarely told either, because there is no required disclosure and no standard testing for PFAS residue in the finished product.
Cyclosiloxanes: Endocrine Disruptors in the Shell
Cyclosiloxanes — specifically D4 (octamethylcyclotetrasiloxane), D5 (decamethylcyclopentasiloxane), and D6 (dodecamethylcyclohexasiloxane) — are silicone compounds used in implant manufacturing and present as breakdown products of silicone gel and shell degradation. They are volatile, bioaccumulative, and persistent in biological tissue.
The European Union classified D4 and D5 as substances of very high concern under REACH regulations, recognizing them as endocrine disruptors and persistent bioaccumulants. D4 is prohibited in wash-off cosmetics in the EU at concentrations above 0.1% — because of its endocrine-disrupting properties and environmental persistence. D5 is restricted in wash-off cosmetics for the same reason. The EU restriction is on a rinse-off personal care product. The implant version sits in tissue for years.
Cyclosiloxanes have been detected in periprosthetic capsule tissue — the fibrous tissue the body forms around the implant — in women who have undergone explant surgery. They have also been detected in lymph nodes draining the breast. Their endocrine-disrupting properties are relevant to the hormonal symptoms many women with BII report: thyroid dysfunction, estrogen dominance patterns, adrenal dysregulation.
Platinum Catalyst
Silicone implants are manufactured using platinum as a crosslinking catalyst during the curing process. Platinum remains in the finished implant — not as a manufacturing residue that can be washed out, but bound into the silicone polymer matrix. Studies have detected platinum in the urine, blood, and hair of women with silicone breast implants at concentrations elevated above baseline population levels.
The critical question is oxidation state. Platinum in its elemental form (Pt⁰) is considered relatively inert. Platinum in ionic or oxidized form (Pt²⁺, Pt⁴⁺) is chemically reactive and can interact with biological systems — including catalyzing oxidation reactions in tissue, interfering with cellular enzymes, and producing neurological and inflammatory effects. Studies have found evidence of both elemental and ionic platinum in the tissue of women with implants. Manufacturers have maintained that the platinum remains in elemental form; independent analyses of capsule tissue have found otherwise in some cases. There is no regulatory requirement to test for platinum speciation in the final implant product.
The Post-Market Study Failure
When the FDA re-approved silicone gel implants in 2006, the approval was explicitly conditional. Mentor and Allergan were required to conduct large, long-term post-market studies — specifically the "Core Studies" — following women for ten years to document rupture rates, reoperation rates, local complications, and systemic health effects including autoimmune and connective tissue disease. This data was supposed to arrive by 2016–2017.
In 2019 and again in 2021, the FDA cited both manufacturers for inadequate study compliance — high dropout rates, incomplete follow-up, missing data. The FDA's 2019 safety communication acknowledged that "the long-term safety and effectiveness of breast implants has not been established to the FDA's satisfaction." This was published thirteen years after the re-approval. The women who received implants in 2006, 2008, 2012, 2016, made their decision under an approval that the FDA itself later said was not supported by adequate long-term data.
BIA-ALCL: The Cancer No One Mentioned at Consultation
Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) is a type of T-cell non-Hodgkin lymphoma that develops in the tissue and fluid surrounding breast implants. It is not breast cancer. It is a lymphoma of the breast pocket. As of current FDA tracking, hundreds of confirmed cases have been reported globally, with the majority associated with textured surface implants — implants with a rough outer shell, originally designed to reduce capsular contracture.
BIA-ALCL is not common in absolute terms. But it is a cancer that develops specifically in women with implants and that was not disclosed as a risk until the FDA's 2019 and 2021 safety communications. Women who had textured implants placed before that disclosure were never told this risk existed. Textured implants have been banned or restricted in several countries, including France, Canada, and members of the EU.
Signs That May Indicate BIA-ALCL
- • Late seroma — fluid collection around the implant, appearing months to years after surgery (not at the time of surgery)
- • Unexplained swelling or asymmetry in one breast
- • A mass in the breast or armpit
- • If diagnosed, requires consultation with an oncologist alongside a plastic surgeon — not a surgical revision alone
BIA-ALCL requires prompt evaluation. If you develop unexplained late seroma with textured implants, do not wait.
Breast Implant Illness: The Symptom Pattern
BII does not have a single diagnostic test or a single universally accepted mechanism. What it has is a documented, consistent pattern of symptoms reported across thousands of women, across implant types, materials, and manufacturers — that frequently resolves following explant surgery. The symptom constellation is broad and overlaps with autoimmune conditions, thyroid disease, chronic fatigue syndrome, fibromyalgia, and neurological disorders — which is part of why it has been so consistently missed.
Commonly Reported Symptoms
The autoimmune overlap is clinically significant. Multiple studies have now found elevated rates of autoimmune conditions — including Sjögren's syndrome, rheumatoid arthritis, systemic lupus, and mixed connective tissue disease — in women with breast implants compared to the general population. A 2018 study published in Annals of Surgery (Coroneos et al.) found statistically elevated rates of several autoimmune and connective tissue diseases in women with silicone gel implants.
Why Implants Can Cause Systemic Symptoms: Proposed Mechanisms
The mechanism of BII is not fully established, which is part of why it remained unrecognized for so long. Several biological pathways have been proposed and are supported by varying levels of evidence.
Silicone Gel Bleed
Silicone gel implants leak silicone molecules through an intact shell — a phenomenon called "gel bleed." This has been documented through both histological and spectroscopic analysis. Silicone particles migrate to regional lymph nodes, liver, and other tissues. The immune system's response to silicone in tissues — whether acute or chronic, local or systemic — is an area of ongoing research and clinical debate.
Implant Shell Degradation and Leachables
The outer shell of silicone implants — and the contents of both silicone and saline implants — contain a range of chemical compounds: platinum (used as a catalyst in silicone manufacturing), cyclomethicones, heavy metals in trace amounts, and other materials. As implants age, the shell can degrade and these compounds can leach into surrounding tissue. Platinum, in particular, is detectable in the urine and hair of some women with implants.
Capsular Contracture and Chronic Inflammation
The body forms a fibrous capsule around any foreign material — including implants. Capsular contracture occurs when this capsule thickens and tightens around the implant. Even without visible contracture, the capsule represents a chronic low-grade inflammatory environment. Chronic systemic inflammation has downstream effects on every body system: hormonal, neurological, immune, metabolic.
Biofilm and Bacterial Colonization
A biofilm — a community of microorganisms enclosed in a protective matrix — can form on implant surfaces. Biofilm-associated infections can be low-grade, sub-clinical, and difficult to detect on standard cultures, while maintaining a chronic immune-activating environment. Some researchers have proposed that biofilm may explain some of the systemic immune dysregulation seen in BII.
Immune Dysregulation and Molecular Mimicry
Some researchers have proposed that silicone or implant-associated proteins may trigger immune responses through molecular mimicry — where the immune system's response to foreign material cross-reacts with the body's own tissues, producing autoimmune-like symptoms. This is consistent with the clinical observation that BII symptoms frequently overlap with recognized autoimmune conditions.
EMF, Mold Inside Saline Implants, and Water Memory: The Layers Nobody Mentioned
Beyond the documented mechanisms of gel bleed and chemical leaching, there are additional compounding factors that some practitioners working in environmental medicine have observed — factors that are rarely discussed in conventional settings because they fall outside the standard biomedical framework. They deserve to be named.
Mold Inside Saline Implants
Saline implants are filled with sterile saline solution at the time of implantation. The filling valve is then sealed — but over time, that valve can degrade, allowing trace amounts of biological material to migrate into the saline cavity. The interior of a saline implant is a warm, dark, enclosed environment with no circulation — ideal conditions for microbial growth if the barrier is compromised.
Mold and fungal growth have been documented inside saline implants in clinical case reports. Women with unexplained neurological symptoms, respiratory problems, or severe chronic illness — who had not improved despite treatment and who explanted — have had mold identified inside their implants upon removal. The biological material is enclosed within the implant shell and not detectable by external imaging. Standard laboratory testing does not assess for this. It can only be discovered by opening the implant after removal and culturing the contents — which is not routinely done unless specifically requested.
Request This at Explant
Ask your explant surgeon to send the implant contents — not just the capsule — to a laboratory for analysis, including fungal culture. This is a straightforward request that is rarely offered but provides important information about what has been living inside your implant.
EMF and Implants: RF Radiation in a Conductive Saline Environment
Saline is electrically conductive. A saline-filled implant sitting within the body — which is itself a conductive medium — exists within the RF-EMF fields generated by the phones, smart watches, laptops, and routers that surround it daily. RF-EMF creates oscillating electrical fields in conductive tissue and fluid. A saline implant in that field may interact with radiation differently than surrounding tissue — concentrating or altering the pattern of electrical disturbance in ways that have not been systematically studied.
What is documented is that RF-EMF affects biological tissue — activating voltage-gated calcium channels, increasing oxidative stress, and disrupting cellular repair during sleep. For women with implants, the precautionary principle is not optional. The breast is not an appropriate location to store a transmitting device.
EMF Precautions — Non-Negotiable for Women with Implants
No phones in the bra — ever
A phone resting against breast tissue is transmitting RF radiation at maximum antenna proximity. The phone-in-bra case series documented multifocal tumors precisely at contact points in young women with no genetic risk factors. With implants, there is the additional concern of the conductive saline environment.
No smart watches
Smart watches emit Bluetooth and cellular signals continuously — against the wrist, all day. There is no safe position for a wireless transmitter worn on the body. Do not wear a smart watch.
No sleeping with a phone near the body
Sleep is the primary window for cellular repair and immune activity. A phone on the nightstand, under the pillow, or on the bed transmits throughout the night — disrupting the repair window when it is most needed. Phone goes on airplane mode or out of the room entirely. No exceptions.
No working near a WiFi router
WiFi routers broadcast continuously at 2.4 GHz and 5 GHz. Working with a router within 3–6 feet — on a desk, on a shelf in the room, mounted to a wall nearby — creates sustained daily exposure to the chest area. Hardwire with ethernet and disable the router's WiFi radio. If you cannot hardwire, move the router to a different room and extend via powerline adapter or wired access point.
No phone on the body — pockets, waistband, or held against the chest
A phone in a front pocket sits near the abdomen and lower chest. Held flat against the chest during a call or laid on the chest while lying down, it is in direct proximity to breast tissue. Apple's own fine print states a minimum separation of 5mm from the body. In practice, phones are worn against skin. Use a bag or purse — not your body — as the carry location.
The car is not a safe EMF environment
A car is a partial Faraday cage — metal body, windows, enclosed space. RF signals from your phone, the car's built-in cellular and WiFi systems, Bluetooth, and hotspot broadcasting bounce and concentrate inside the cabin rather than dissipating. Bluetooth is not a necessity. A hotspot is not a necessity. These are habits, not requirements. For someone who is sick, the options for optional tech use are gone — phone on the dash or in a bag, airplane mode when not actively navigating, car Bluetooth and hotspot off, no streaming. The question is not "when do I need it" — it is "do I actually need it at all."
For measurement: An Acoustimeter AM-10 or similar RF meter will show you what is actually transmitting in your environment and at what levels. Measure your desk, your bed, your car interior. The numbers make the abstract concrete — and make it much easier to prioritize what to change first. See the Apothecary EMF section and the full Non-Native EMF module for the complete evidence base and mitigation guide.
EMF, Mold, and the Amplification Pattern
Research in environmental and biological science has indicated that certain frequencies of electromagnetic fields appear to stimulate mold growth, increase mold toxin (mycotoxin) production, and accelerate fungal sporulation. If mold is present inside a saline implant — or in the surrounding capsule environment — chronic EMF exposure from devices worn or carried close to the body may worsen the biological burden of that mold presence.
This is an area of emerging investigation rather than established consensus. But it is consistent with clinical observations in practitioners working with mold-illness patients: those with high EMF environments frequently show more severe mold-related symptoms than those without. Reducing EMF exposure is a standard recommendation in mold illness recovery protocols — and is particularly relevant for people with BII whose symptom picture includes cognitive dysfunction, fatigue, and inflammatory presentations consistent with biotoxin illness.
Water Memory and the Environment of the Implant
The work of Dr. Masaru Emoto and Dr. Luc Montagnier has raised the question of whether water retains information from its environment — a concept referred to as water memory. Emoto's crystallography research documented that water exposed to different environmental conditions (including chaotic electromagnetic environments, pollution, and emotional disturbance) formed distorted crystal structures, while water in coherent, clean environments formed organized, symmetrical crystals.
Applied to saline implants: the water inside a saline implant sits, for years, in a chronic inflammatory environment — surrounded by the body's immune response, exposed to whatever EMF fields the woman's daily life generates, and in some cases potentially harboring microbial growth. If water retains structural memory of its environment — as this body of research suggests — the biological state of that water after years in an implant cavity may be meaningfully different from the sterile saline that went in. This is a framework that requires more research. It is consistent with the broader evidence that the quality, structure, and electromagnetic environment of water affects its biological activity — see the Water page for more on water structuring and biological function.
Testing That Shows the Damage — and How to Get It Ordered
Standard blood work — CBC, CMP, TSH — does not see BII. It is not designed to. It will come back normal while a woman is profoundly ill, and that "normal" will be used against her. The testing that actually shows what implants do to the body requires a different framework, different markers, and a practitioner who will order them.
The most strategic time to run this panel is before explant. Pre-explant testing establishes the baseline — the inflammatory state, immune dysregulation, and toxic burden while the implants are still in. That documentation serves two purposes: it establishes medical necessity for surgical intervention, and it gives you the before/after comparison that shows whether the body is recovering post-explant. Repeat key markers at 3, 6, and 12 months after removal.
Imaging — Structural Integrity
- • Breast MRI without contrast — gold standard for implant integrity; detects silent rupture, intracapsular vs. extracapsular rupture, gel migration. Do not accept gadolinium contrast — gadolinium deposits in brain tissue with repeated use. See Drug Library.
- • Axillary lymph node ultrasound — specifically to assess whether silicone particles have migrated to regional lymph nodes; often missed on general breast ultrasound
- • Thermography — radiation-free infrared imaging; shows asymmetric heat signatures consistent with inflammation and vascular changes; useful as a baseline and for monitoring
- • Standard ultrasound — detects seroma (fluid collection around the implant); less sensitive than MRI for shell integrity but accessible and lower cost
Inflammation & Immune Activation
- • TGF-β1 (Transforming Growth Factor Beta 1) — elevated in BII; drives fibrosis, capsular contracture, and systemic fibrotic response; also elevated in biotoxin illness and mold exposure — a dual marker
- • High-sensitivity CRP (hs-CRP) — more sensitive than standard CRP for detecting low-grade chronic inflammation
- • ESR (erythrocyte sedimentation rate) — nonspecific inflammatory marker; often elevated in BII
- • IL-6 (interleukin-6) — pro-inflammatory cytokine; elevated in many BII cases; correlates with fatigue severity
- • ANA (antinuclear antibody) with reflex panel — screening for systemic autoimmune activity; if positive, reflexes to anti-dsDNA, anti-Sm, anti-SSA/SSB, anti-Scl-70, anti-Jo-1
- • Complement C3 and C4 — may be low in active autoimmune disease; C4a is specifically elevated in mold/biotoxin illness
- • Complete lymphocyte panel with CD4/CD8 ratio — T-cell immune dysregulation
- • CD57 (NK subset) — depleted in chronic illness including BII, mold illness, and tick-borne disease; a marker of immune exhaustion
- • NK cell activity — natural killer cell function; often suppressed in chronic inflammatory illness
Mold & Biotoxin Burden
This group is especially relevant for women with saline implants, who may have mold growing inside the implant cavity. BII and mold illness overlap significantly in symptom picture; women with both have a far heavier burden to clear.
- • Urine mycotoxins — GPL-MycoTOX profile (Great Plains Laboratory) or Vibrant Wellness MycoTOX; tests for aflatoxins, ochratoxin A, trichothecenes, zearalenone, and other fungal toxins; urine, no blood draw required
- • C4a (complement activation fragment) — elevated in mold/biotoxin illness; not easy to order through standard labs but available through specialty testing (Quest, LabCorp with physician authorization)
- • MMP-9 (Matrix Metalloproteinase 9) — elevated in mold illness and chronic inflammatory conditions; can be ordered through standard labs
- • MSH (Melanocyte-Stimulating Hormone) — depleted in biotoxin illness (Shoemaker protocol marker); low MSH associated with chronic pain, sleep dysregulation, and immune dysfunction
- • TGF-β1 (see inflammation panel above — also a biotoxin marker)
- • VEGF (Vascular Endothelial Growth Factor) — elevated in some mold illness and chronic inflammatory presentations; can be ordered by physician
Heavy Metals & Implant-Specific Markers
- • Urine heavy metals panel — specifically include platinum, titanium, aluminum; unprovoked baseline urine is cleaner for tracking chronic exposure; provoked testing (with DMSA/DMPS) carries risks in a depleted body and should only be done with practitioner oversight
- • Serum platinum — specific test for platinum from silicone catalyst; not included in standard metal panels; must be requested by name
- • Hair tissue mineral analysis (HTMA) — shows chronic exposure pattern over months; not subject to the hourly fluctuations of blood testing; useful for mineral depletion and heavy metal accumulation pattern
- • Silicone antibody testing — available through specialty labs (Immunosciences Lab); tests IgG, IgM, IgA immune response to silicone compounds
- • MELISA test — an advanced lymphocyte transformation test; assesses immune reactivity to metals and silicone; available through MELISA Diagnostics (Europe-based; US samples can be shipped)
- • LTT (Lymphocyte Transformation Test) — tests immune reactivity to specific materials; MELISA is the more validated form of this test
Hormonal, Metabolic & Liver Function
- • Full thyroid panel — TSH, free T3, free T4, reverse T3, TPO antibodies, thyroglobulin antibodies; BII frequently presents with thyroid involvement, often with "normal" TSH but low free T3
- • Complete sex hormone panel — estradiol, progesterone, testosterone total and free, DHEA-S, SHBG
- • 4-point salivary cortisol — adrenal axis function; AM/noon/PM/bedtime to assess the full diurnal curve
- • Insulin, fasting glucose, HbA1c — metabolic inflammation and insulin resistance
- • GGT (Gamma-Glutamyl Transferase) — Phase II liver detoxification indicator; elevated GGT signals compromised glutathione production and detox capacity; more sensitive than ALT/AST for chronic toxic load
- • ALT, AST (in standard CMP) — liver inflammation markers
- • Homocysteine — methylation pathway marker; elevated homocysteine indicates impaired methylation, which is required for both detoxification and immune regulation
Detoxification Capacity & Nutrient Depletion
These tests answer a critical question before recovery begins: does this body have the genetic and nutritional infrastructure to actually clear what the implants put in?
- • Organic acids test (OAT) — comprehensive: mitochondrial function, detoxification capacity, gut dysbiosis markers, oxalate burden, B-vitamin status, neurotransmitter metabolites; Great Plains Laboratory or Genova Diagnostics
- • MTHFR genotyping (C677T and A1298C variants) — methylation capacity; women with compound heterozygous or homozygous MTHFR mutations have significantly impaired detoxification and need different support
- • COMT genotyping — catechol-O-methyltransferase; affects estrogen metabolism and neurotransmitter processing; relevant to hormonal symptoms in BII
- • GSTM1 / GSTP1 genotyping — glutathione S-transferase genes; null variants are common and indicate significantly reduced capacity to conjugate toxins for elimination
- • RBC magnesium (not serum magnesium — serum is meaningless) — intracellular magnesium; depleted in chronic inflammation and essential for hundreds of enzymatic reactions
- • Zinc and copper (serum) — copper-zinc ratio; copper dysregulation is common in chronic illness and immune dysfunction
- • Ferritin — iron storage; low in many women with BII; high ferritin is also an inflammatory marker
- • B12 (serum) and active B12 (holotranscobalamin) if B12 is borderline
- • B6 as active P5P form — standard B6 testing misses functional deficiency
- • RBC folate — more accurate than serum folate for tissue stores
- • Omega-3 index — percentage of EPA + DHA in red blood cell membranes; below 4% indicates significant pro-inflammatory fatty acid ratio
Post-Surgical Testing — At Explant
- • Capsule pathology with CD30 immunostaining — standard pathology of the capsule; CD30 staining is required to rule out BIA-ALCL (anaplastic large cell lymphoma); must be specifically requested — it is not included in standard pathology unless ordered
- • Capsule bacterial and fungal culture — assesses for biofilm-associated infection and fungal growth in the capsule tissue; this is separate from implant contents culture
- • Implant contents culture (saline separately from gel if applicable) — assesses mold and bacterial growth inside the implant itself; must be specifically requested before surgery; implants are often disposed of without culturing unless the patient requests it in advance
- • Capsule tissue for cyclosiloxane analysis — available through specialty environmental labs; not standard; documents which silicone degradation products are present in the tissue
How to Get Your Doctor to Order These
Most of the markers above can be ordered — the challenge is getting a physician to order them. Several strategies work:
- • Frame it as ruling out systemic autoimmune disease — don't lead with "I think my implants are making me sick." Lead with: "I need a comprehensive autoimmune and inflammatory workup — I've had a foreign body implant for X years and I'm experiencing systemic symptoms that haven't been explained." This framing is clinically defensible and harder to dismiss.
- • Bring documentation — the FDA's 2019 and 2021 safety communications specifically name systemic symptoms as implant-associated. Print the FDA's breast implant safety page and bring it. Physicians cannot dismiss FDA-documented safety concerns the way they dismiss patient self-reports.
- • Use direct-to-consumer lab ordering — for tests a physician won't order: Ulta Lab Tests, Everly Well, Function Health, Quest Diagnostics Patient Direct, and LabCorp Patient Direct allow patients to order many standard labs without a physician. Specialty tests (mycotoxins, MELISA, silicone antibodies) still require a physician or direct contact with the specialty lab.
- • Find a practitioner who already understands this picture — a functional medicine, environmental medicine, or integrative practitioner is far more likely to order comprehensively than a primary care physician. An explant-specialized surgeon can also order or refer for pre-operative workup. The BII community maintains practitioner lists.
- • Document refusals — if a physician refuses to order specific tests, ask them to document the refusal in your chart with the clinical reasoning. Many will reconsider when asked to put it in writing. If they don't, you have documentation for your records and for a second-opinion visit.
- • Request CPT codes — when ordering, ask which CPT codes will be used for billing. This allows you to verify coverage in advance and tells you which tests may be subject to prior authorization. Tests ordered as "evaluation of foreign body implant" often have better coverage than more general wellness labs.
BII Testing Checklist
A printable reference with the complete testing list organized by category, direct-to-consumer lab options, and the exact language to use with your physician — formatted to bring to a medical appointment.
BII Testing ChecklistExplant: What "Removal" Actually Means
Not all implant removal is equal. When an implant is removed without the surrounding capsule, silicone particles, gel bleed residue, and any biofilm-contaminated tissue remain in the body. For women with BII, the type of removal matters significantly for recovery outcomes.
Standard Removal / Simple Capsulectomy
The implant is removed. The capsule may be partially removed or left in place. Any silicone that has migrated beyond the capsule remains. Many people with BII who undergo standard removal report incomplete symptom resolution.
En Bloc Capsulectomy
The implant and its surrounding capsule are removed together, intact — preventing spillage of capsule contents and any trapped silicone, bacteria, or reactive tissue into the surgical field. This is the preferred approach for BII and ruptured implants. Requires a surgeon specifically trained and experienced in this technique. Not all plastic surgeons perform en bloc removal.
Questions to Ask a Prospective Explant Surgeon
- • "Do you perform en bloc capsulectomy? How many have you done?"
- • "Will you remove the entire capsule intact, or will you open the capsule during removal?"
- • "What is your protocol if you find a ruptured implant or capsule adhesion to surrounding tissue?"
- • "Will you send the capsule to pathology for assessment including BIA-ALCL testing?"
- • "What does your post-operative support look like for patients with BII?"
When Surgeons Refuse
This is where many women hit a wall. They have done the research. They know they want en bloc capsulectomy. They have found a surgeon. And the surgeon — sometimes the same surgeon who placed the implants — tells them it is not necessary, not indicated, or not something they offer.
This refusal takes several forms, and it helps to know what is actually driving each one.
"En bloc isn't necessary in your case"
This is the most common refusal — and it is frequently delivered as clinical judgment when it is actually a training and capability issue. En bloc capsulectomy is technically demanding. It requires dissecting the capsule free from surrounding tissue — including the chest wall, ribs, and pectoral muscle — without perforating it. Not every plastic surgeon has trained in this technique or performs it with the frequency required to do it well. A surgeon who cannot safely perform en bloc will often frame the limitation as a clinical position: "the capsule looks fine," "en bloc is overkill for your situation," "partial capsulectomy is the standard of care." What they are not telling you is that they do not offer it, and are not offering you a referral to someone who does.
"BII isn't a real diagnosis"
Some surgeons — particularly those who built a practice placing implants — will challenge the premise that implants caused the symptoms at all. They may acknowledge BIA-ALCL (because the FDA has formally named it) while dismissing systemic BII as anecdotal. In some cases this is genuine skepticism; in others, there is a financial conflict of interest — a surgeon whose practice revenue depends on placement consultations has something to lose from a narrative that implants make women chronically ill. This does not mean all surgeons who question BII are acting in bad faith. It does mean you should ask whether the surgeon performing your consultation has placed implants, how recently, and whether their practice still offers placement. The answers tell you something about where they sit in this landscape.
Refusing to remove infected, damaged, or necrotic tissue
This is the most consequential refusal. When a surgeon opens the surgical field and finds contaminated, infected, or necrotic tissue — and does not fully debride it — they leave the biological source of the problem behind. Biofilm-laden capsule tissue, mold-contaminated saline implant contents that have spilled into the pocket, silicone granulomas adhered to the chest wall, or necrotized capsule tissue are not self-resolving once the implant is out. They continue to drive inflammation, immune dysregulation, and systemic symptoms. Women who undergo standard removal and do not improve — or worsen — often discover in subsequent imaging or surgery that infected or damaged tissue was left in place at the first operation.
Refusing to send tissue to pathology
After removal, the capsule and any associated tissue should be sent to pathology — for histological assessment and, where indicated, BIA-ALCL testing with CD30 immunostaining. This is not optional. It is the only way to determine whether abnormal cells, fungal growth, or early malignancy are present in the tissue that has been living against your immune system for years. Some surgeons dispose of explanted material without sending it to pathology unless the patient specifically requests it. Request it in writing before surgery. Get confirmation that the material will be sent, to which laboratory, and how you will receive the results.
Insurance and time pressure
En bloc capsulectomy takes significantly longer in the operating room than simple implant removal. Operating room time is billed by the minute. Many insurance plans that cover removal do not cover the additional time and complexity of full en bloc resection. A surgeon in a high-volume practice who takes fifteen minutes per removal versus ninety minutes for a complete en bloc will see a significant revenue difference per case. This is not the only driver of refusal — but it is a real structural pressure that influences what surgeons offer and how they counsel patients. If your surgeon is moving quickly toward a simpler procedure, it is appropriate to ask directly: "Does insurance coverage affect what type of removal you are recommending to me?"
What to Do When You Hit Refusal
- • Get a second opinion from a surgeon who specializes in explant — not a general plastic surgeon who also does explant. The BII community maintains surgeon lists based on patient outcomes. A surgeon who performs fifteen en bloc procedures a week versus one who does it occasionally are not equivalent options.
- • Do not let a surgeon talk you into partial capsulectomy if you want en bloc. You can consent to a procedure, and you can decline one. A surgeon who pressures you into accepting less than you came in requesting is telling you something about how the rest of the clinical relationship will go.
- • Request the surgical report in writing after any procedure. It will document exactly what was removed, what was found, and what was left in place. If you discover that tissue was left behind that should have been removed, you have documentation for a follow-up consultation with a different surgeon.
- • Request that implant contents and capsule be cultured — not just sent for standard pathology. Standard pathology assesses cell structure; culture assesses microbial growth, including mold and bacteria. These are separate requests and must both be made explicitly before surgery.
- • If you cannot find a qualified surgeon locally — women frequently travel for en bloc capsulectomy by an experienced surgeon. This is a one-time procedure. The distance is worth it.
Questions to Ask a Prospective Explant Surgeon — Full List
- • "Do you perform en bloc capsulectomy? How many have you done in the past year?"
- • "Will you remove the entire capsule intact, or will you open the capsule during removal?"
- • "What is your protocol if you find a ruptured implant or capsule adhesion to the chest wall?"
- • "What do you do when you find infected, contaminated, or damaged tissue — do you debride fully or leave it?"
- • "Will you send the capsule to pathology? Will you also send it for culture, including fungal culture?"
- • "Will you culture the implant contents separately from the capsule?"
- • "Do you still place breast implants? What percentage of your current practice is placement versus explant?"
- • "Does my insurance coverage affect what type of removal you recommend to me?"
Supporting Recovery After Explant
Many women report significant symptom improvement in the weeks and months following en bloc explant. Recovery is a process — the body's detoxification capacity, immune system, and hormone axes all need support after years of chronic inflammation and toxic burden. But the order in which you approach recovery matters enormously.
Establish Redox Before You Detox
The most common mistake in BII recovery is pushing aggressive detox protocols on a body that does not yet have the cellular energy to handle them. Mobilizing stored toxins — silicone particles, heavy metals, chemical residues — without adequate detoxification capacity means those toxins circulate and redistribute rather than clear. This can make a sick body sicker.
Redox refers to your body's reduction-oxidation capacity — its ability to produce cellular energy (ATP), neutralize oxidative stress, and run the enzymatic reactions that detoxification depends on. A body depleted by years of chronic inflammation, poor sleep, EMF exposure, and nutrient deficiency has impaired redox capacity. Attempting to detox this body aggressively is like trying to run a drainage system with no pump.
Establish the foundation first:
- ●EMF environment — the sleep environment is the most critical space. This means more than phones and routers. Metal bed frames concentrate fields. Power cords run under mattresses. Heating pads, electric blankets, magnets, and pulse devices sit on or near the body for hours. Smart meters on exterior bedroom walls, AC units near the head, and bad wiring inside the walls all contribute. The goal is a biologically quiet sleep space. Cellular repair happens during deep sleep — it cannot proceed in a field of non-native EMF. Start here. See the EMF page for a complete audit guide.
- ●Lighting — remove LED lighting from the home where possible and replace with low-wattage 2700K incandescent bulbs. No artificial light after dark, or as little as possible. Seeing the sunrise daily is non-negotiable — this is the signal that sets every hormonal cascade that follows. No glasses, no sunscreen, eyes toward the sky. The safest approach after dark is simply lowering light — melanopsin receptors in the skin respond to light, not just the eyes, so glasses alone do not fully protect melatonin. Blue-blocking glasses (550nm) can help if some light is unavoidable, but they are not a substitute for reducing light exposure itself. These are free interventions that restore the hormonal architecture repair depends on.
- ●Water — drink spring water. Natural spring water carries coherent structure, minerals, and biological information that no filtered or processed source replicates. Find a local spring at findaspring.com and test before drinking. Commercially bottled spring water is acceptable — even in plastic — over RO or tap. RO water is dead water; adding minerals or Quinton back in addresses minerals but does not restore coherence, and is not the recommendation. For additional coherence and structuring, place your water on a YouMatrix H2O disk before drinking. Use filtration (whole-house carbon or RO) for bathing and showering — not for drinking. Intracellular hydration is a prerequisite for every detoxification pathway.
- ●Real whole food — practitioner-guided. Most women in active BII are highly reactive. What works for a healthy body may aggravate a compromised one. Avoid processed seed oils, refined sugar, alcohol, and packaged foods. Beyond that, individual food reactions vary significantly and are best worked through with a practitioner who knows your case. The liver runs phase I and phase II detoxification — it requires real food, not restriction. Nourish, do not restrict. If you are unsure where to start, work with someone who can guide you through the reactivity.
- ●Rest — not pushing — a depleted body signals through fatigue. Honor that signal. Aggressive exercise, aggressive protocols, and aggressive supplement stacks during this phase worsen mitochondrial burden. Gentle movement, walking, lymphatic support, and rest are appropriate. The body is doing the heavy work internally.
The Body Is Designed to Drain — Create the Conditions
The body does not need to be forced through detoxification. It needs the conditions that allow it to drain on its own. When EMF is reduced, circadian rhythm is restored, sleep is deep, and water is coherent and structured, the body's innate drainage systems come back online. Attempting to force heavy metal clearance or mold detox protocols on a body that has not yet reached this baseline can make things significantly worse — mobilizing stored toxins faster than elimination pathways can handle them, causing redistribution, increased symptom burden, and systemic aggravation.
The foundation is the protocol. Coherence, circadian alignment, low EMF, and structured spring water are not preparation for detox — they are the mechanism. The body was built to do this work when the interference is removed.
- ●Liver support through food — adequate real food, sulfur-rich vegetables (onions, garlic, cruciferous vegetables), clean structured spring water. The liver requires fuel and cofactors, not stimulants or aggressive binders.
- ●Lymphatic movement — gentle walking, manual lymphatic drainage massage, deep diaphragmatic breathing. The lymphatic system has no pump of its own — movement is the pump. This is supportive, not aggressive.
- ●Spring water — local or commercially bottled (findaspring.com). Use a YouMatrix H2O disk for additional structuring and coherence. Every drainage pathway in the body is water-dependent.
- ●Practitioner support — if you are not moving through recovery or need more targeted support, working with a practitioner who has access to the YouMatrix tools and protocols may offer another level of assistance. These tools work with the body's coherence and field — not against it.
Warning: Supplemental Glutathione & Breast Cancer Metastasis
Glutathione is widely recommended in detoxification and BII recovery protocols. However, research has documented that elevated glutathione levels can promote breast cancer cell survival and metastasis — glutathione's antioxidant activity protects cancer cells from the oxidative stress that would otherwise destroy them, and facilitates their migration and invasion of surrounding tissue. This is not a theoretical concern. It is a documented mechanism with direct relevance to any woman with a history of breast implants, who carries elevated breast cancer risk, or who has not yet completed comprehensive imaging to rule out malignancy.
Do not supplement with liposomal glutathione, NAC (as a glutathione precursor), or glutathione IV therapy without a full workup and practitioner oversight that includes ruling out active cancer. Support glutathione through whole foods only — cruciferous vegetables (broccoli, cauliflower, Brussels sprouts), alliums (garlic, onions), and liver — where it is delivered with the complete matrix of co-factors that regulate its activity rather than as a concentrated isolated supplement.
Warning: Chlorella Can Make a Sick Body Sicker
Chlorella is commonly recommended as a heavy metal binder and detoxification support. In a compromised, depleted body — which describes most women in active BII — chlorella can mobilize more toxins than the elimination pathways can handle, causing increased symptom burden, headache, fatigue, and systemic aggravation. It can also cause immune reactions in people with mold or algae sensitivities. Some women in BII recovery may never tolerate chlorella at all, regardless of where they are in the process. Moringa is a gentler option worth exploring — it supports detoxification pathways, provides a broad nutrient profile, and is better tolerated by reactive individuals. Neither is a starting point. Work with a practitioner before introducing either.
Immune Regulation and Inflammation
- • Real whole food — the clearest guideline is to remove the industrial inputs: processed seed oils, refined sugar, alcohol, and packaged foods. What remains is real food. Eat it. The amounts and ratios that work for your body are individual — macro prescriptions and glucose anxiety cause their own harm, and 30 years of clinical practice shows that eating disorders, orthorexia, and over-restriction do as much damage as the food itself. Nourish, do not restrict. If EMF, sleep deprivation, and lack of sunlight are still in the picture, they are dysregulating metabolism more than any real food choice — address the environment alongside the food.
- • Gut microbiome restoration — fermented foods, prebiotic fibers; the gut-immune axis is central to autoimmune recovery
- • Sleep — the single most powerful immune-regulatory intervention; 7–9 hours in a dark, low-EMF environment
- • Sunlight — morning light for cortisol curve normalization and circadian reset; midday UVB for skin-produced vitamin D (not supplemental isolated vitamin D)
Hormonal Recovery
BII is frequently associated with thyroid and adrenal dysfunction — both from the chronic inflammatory burden and from xenoestrogenic and immune effects of implant materials. Comprehensive hormonal assessment (as described in the testing section above) should inform any targeted support. See the HRT & Hormone Disruptors page for the full framework on hormonal recovery, estrogen dominance, and adrenal support.
— Cheyenne Burnett, Explant Secrets Podcast, Episode 6: Your Essential Testing Guide for BII
Essential Listening & Community
Explant Secrets Podcast — Cheyenne Burnett
TEDx speaker and Women's Health Warrior. Episode 7 “Your Essential Testing Guide: Testing for Breast Implant Illness” (23 min, published Jan 18 2024) is a comprehensive resource on testing beyond standard blood work.
Explant Secrets YouTube & Instagram
Video content on BII, testing, explant surgery, and recovery. @explantsecretspodcast on Instagram.
YouTube →Key Studies
Coroneos et al. — Breast Implants & Autoimmune Disease (Annals of Surgery, 2019)
FDA-commissioned study; 100,000+ women with silicone gel implants. Elevated rates of autoimmune and connective tissue disorders confirmed statistically. Sjogren's, rheumatoid arthritis, systemic lupus, scleroderma, and others.
PubMed →FDA Safety Communication — BIA-ALCL (2019) & Boxed Warning (2021)
FDA's formal acknowledgment of BIA-ALCL risk and BII. Required boxed warning and patient decision checklist now mandatory for all breast implant procedures. Full device labeling requirements.
FDA.gov Breast Implant Risks →Breast Implant Illness — Systematic Review (Hindawi, 2022)
Characterizes BII autoimmune disorders and associated symptoms across the current literature. Confirms BII as a recognized clinical entity with documented autoimmune overlap.
Full Text (Hindawi) →Finding an En Bloc Surgeon
Breast Implant Safety Alliance (BISA)
Surgeon directory and patient resources for finding practitioners who specialize in en bloc capsulectomy for BII. Patient advocacy and informed consent resources.
thebreastimplantsafetyalliance.org →Related Pages
Mammograms & Breast Health
Mammogram overdiagnosis, false positives, dense breast tissue, phone-in-bra case series, and what to ask your radiologist.
Breast Health page →Hormone Disruptors & HRT
Hormonal recovery framework, estrogen dominance, and adrenal support — relevant to post-explant hormonal recovery.
HRT & Bioidentical Hormones →Drug Reference Library — Contrast Agents
Gadolinium deposition from MRI contrast — relevant for women considering MRI to assess implant integrity; request non-contrast breast MRI where possible.
Pharmacology Library →Transcript
Estimated runtime: ~3:30–4:00
For years, tens of thousands of women reported the same experience. They got breast implants. And then — months, sometimes years later — they weren't well. Fatigue they couldn't explain. Brain fog. Joint pain. Hair loss. Rashes. Depression. They went to doctors. They ran standard labs. They were told everything was normal. The implants were fine. The symptoms were probably stress.
In 2021, the FDA required that every breast implant manufacturer add a boxed warning — the most serious warning designation on a medical device — acknowledging that breast implants are associated with systemic symptoms including fatigue, cognitive dysfunction, joint pain, and depression. That acknowledgment did not come from nowhere. It came from the women who had been documenting this for decades.
The FDA's action covered two things. First, Breast Implant Illness — the systemic symptom picture I just described. Second, BIA-ALCL: Breast Implant-Associated Anaplastic Large Cell Lymphoma. This is a lymphoma — not breast cancer — that develops in the tissue around breast implants. It's primarily associated with textured surface implants, which have now been banned or restricted in France, Canada, and several EU countries. The United States still permits them.
The informed consent checklist now required by the FDA means that women getting implants today must be told these risks before surgery. Women who had implants placed before that — the majority of women with implants — were never told any of it. They consented to a procedure without information the FDA now considers essential.
Breast Implant Illness is a systemic condition. The symptoms are broad: fatigue, brain fog, joint and muscle pain, hair loss, dry eyes, rashes, depression, thyroid dysfunction, autoimmune-like presentation. They overlap with lupus, Sjögren's syndrome, fibromyalgia, chronic fatigue. Which is exactly why standard workups miss it — because no single test result, no ANA, no thyroid panel, captures the whole picture.
Research published in the Annals of Surgery — an FDA-commissioned study of over 100,000 women with breast implants — found statistically elevated rates of connective tissue disease, autoimmune conditions, and inflammatory disorders compared to the general population. This is peer-reviewed data. It is not a forum post.
The mechanisms include silicone gel bleed through an intact shell, implant shell degradation and chemical leaching, chronic inflammation from the fibrous capsule the body forms around any foreign object, and possibly biofilm — low-grade bacterial colonization on implant surfaces that maintains a chronic immune-activating environment without producing the kind of obvious infection that standard tests detect.
Standard blood work doesn't adequately evaluate BII. A comprehensive workup includes a full autoimmune panel — ANA, specific autoantibodies — inflammatory markers, complete thyroid and hormone assessment, organic acids test, and heavy metals. MRI without contrast is the gold standard for assessing whether your implants are structurally intact. And there are specialized tests — lymphocyte transformation testing, silicone antibody testing — that assess immune reactivity to the specific materials in your implants.
If you decide to explant, what type of removal matters enormously. Standard removal leaves the capsule — and everything in it — behind. En bloc capsulectomy removes the implant and the entire surrounding capsule intact, in one piece, preventing any spillage of capsule contents into the surgical field. Women with BII who report significant improvement after explant have almost universally undergone en bloc removal, not standard.
Not every surgeon performs en bloc. Ask directly. Ask how many they have done. If the answer is vague, find someone who specializes.
Recovery from BII is a process. Many women feel dramatic improvement within weeks of explant. For others, it takes longer — the body's detoxification of silicone, chemical residues, and the chronic inflammatory burden from years of BII takes time and support. Liver support. Lymphatic drainage. Heavy metal clearance under clinical guidance. Gut restoration. Hormonal recovery — thyroid and adrenal function both commonly need support post-explant.
This is not a simple medical procedure followed by a quick return to normal. It is a whole-body recovery. Treating it that way — with the support your physiology actually needs — makes a difference.
If you have implants and you have not been well — in ways that your doctors have not been able to explain — BII deserves to be on the differential. Not because implants cause problems in every woman. But because the FDA now formally acknowledges that they cause problems in some women. And because the women who documented this for decades before the FDA caught up — who were dismissed, who were told their symptoms were in their head — deserve to have their experience taken seriously. The resources are in the Resources tab. The testing guide is in the written article. Start there.